Intelligence / Semaglutide

Semaglutide

Prescription Only
GLP-1 Agonist
Schedule
S4
Prescription Only
Enforcement
Tightening
Low Risk
Providers
12
Access: Clear
Key Facts
Schedule 4 - Prescription Only
GLP-1 receptor agonist
TGA-approved branded products available
Compounded versions under increased scrutiny
Import restrictions tightened February 2026

Overview

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It is available in Australia as branded products (Ozempic, Wegovy) and through compounding pharmacies. The TGA has increased regulatory scrutiny on compounded versions following supply shortages.

Australian Scheduling

Schedule 4 (Prescription Only). TGA-approved branded products are listed on the ARTG. Compounded semaglutide is available under pharmacy compounding exemptions. Import restrictions were tightened in February 2026.

Access Pathway

Available through telehealth clinics and compounding pharmacies. Branded versions (Ozempic, Wegovy) can be prescribed by any GP. Compounded versions are available through specialised providers but face increasing regulatory scrutiny.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Annals of internal medicine1 Sept 2026
Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.
Diabetes, obesity & metabolism31 Aug 2026
Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study".
Clinical nutrition ESPEN31 Aug 2026
Reply - Letter to the Editor: Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study.
Clinical nutrition ESPEN31 Aug 2026
Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis
International Journal of Obesity29 Aug 2026
Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial
Journal of Gastroenterology28 Aug 2026
Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD
Journal of Clinical Endocrinology & Metabolism27 Aug 2026
Transcriptomic Changes Elicited by Semaglutide in Human Ventricular Tissue Support Cell Survival and Lipid Metabolism
Circulation: Heart Failure27 Aug 2026
Data and Temporal Risk Concerns of Semaglutide and NAION
JAMA Ophthalmology27 Aug 2026
Data and Temporal Risk Concerns of Semaglutide and NAION—Reply
JAMA Ophthalmology27 Aug 2026
Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.
Obesity26 Aug 2026
A Randomized Controlled Study of Dose-tapering Semaglutide for Weight-Loss Maintenance trial posted on ClinicalTrials.gov
ClinicalTrials.gov25 Aug 2026
Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide.
Obesity facts25 Aug 2026
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease.
Clinical journal of the American Society of Nephrology : CJASN25 Aug 2026
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies.
The American journal of managed care25 Aug 2026
Synthetic Versus Reference Semaglutide for Weight Management: Reporting Gaps and Clinical Claims.
Diabetes, obesity & metabolism24 Aug 2026
Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Naunyn-Schmiedeberg's Archives of Pharmacology22 Aug 2026
A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders.
Science Advances21 Aug 2026
GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.
Inflammatory Bowel Diseases21 Aug 2026
GLP-1 and GLP-1/GIP agonists in psoriasis: A real-world cohort study on healthcare resource usage.
Journal of the European Academy of Dermatology and Venereology21 Aug 2026

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.